(R)-ethyl 2-bromobutyrate | 130251-07-9

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: (R)-ethyl 2-bromobutyrate
• 英文别名: ethyl (R)-2-bromobutyrate；Ethyl alpha-bromobutyrate, (+)-；ethyl (2R)-2-bromobutanoate
• CAS: 130251-07-9
• 化学式: C₆H₁₁BrO₂
• 分子量: 195.056
• InChiKey: XIMFCGSNSKXPBO-RXMQYKEDSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  9
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (R)-ethyl 2-bromobutyrate 、 9-{4-[(5-methyl-2-phenyloxazole-4-yl)methoxy]-3-methoxybenzyl}-9 H-carbazole-4-ol 在 sodium hydride 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 1.5h， 以95%的产率得到
  参考文献：
  名称：

  CARBAZOLE DERIVATIVE, SOLVATE THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF

  摘要：

  公开号：

  EP1852433B1
• 作为产物：
  描述：

  乙醇 、 (R)-2-溴丁酸 在 硫酸 作用下， 以 1,2-二氯乙烷 为溶剂， 生成 (R)-ethyl 2-bromobutyrate
  参考文献：
  名称：

  Herbicidal Activity of Beflubutamid Analogues as PDS Inhibitors and SAR Analysis and Degradation Dynamics in Wheat

  摘要：

  DOI：

  10.1021/acs.jafc.3c04733

文献信息

• GC Separation of Enantiomers of Alkyl Esters of 2-Bromo Substituted Carboxylic Acids Enantiomers on 6-TBDMS-2,3-di-alkyl- β- and γ-Cyclodextrin Stationary Phases
  作者：Ivan Špánik、Darina Kačeriaková、Jan Krupčík、Daniel Wayne Armstrong

  DOI：10.1002/chir.22310

  日期：2014.6

  The gas chromatographic separation of enantiomers of 2‐Br carboxylic acid derivatives was studied on four different 6‐TBDMS‐2,3‐di‐O‐alkyl‐ β‐ and ‐γ‐CD stationary phases. The differences in thermodynamic data ΔH and –ΔS} for the 15 structurally related racemates were evaluated. The influence of structure differences in the alkyl substituents covalently attached to the stereogenic carbon atom, as

  在4种不同的6-TBDMS-2,3-di-O-烷基-β-和γ-CD固定相上研究了2-Br羧酸衍生物对映体的气相色谱分离。热力学数据的差异 ΔH和–ΔS}对15个与结构相关的外消旋体进行了评估。详细研究了共价连接到立体碳原子上的烷基取代基以及同源分析物的酯基中结构差异的影响，以及改性β-和γ-环糊精衍生物的选择性。环糊精空腔的大小，以及6-TBDMS-β-CD的2和3位的烷基取代基的延伸，也影响了它们的选择性。对映体分离的质量主要受分子酯基团的烷基链影响，这似乎与所用的CD固定相无关。在某些情况下，分离是由于外部吸附而不是与手性选择剂形成包合物而发生的。手性26：279–285，2014。©2014 Wiley Periodicals，Inc.
• DERIVATIVES, REAGENTS, AND IMMUNOASSAY FOR DETECTING LEVETIRACETAM
  申请人：Ouyang Anlong

  公开号：US20100317024A1

  公开（公告）日：2010-12-16

  Levetiracetam (LEV) derivatives, methods for synthesizing LEV derivatives, and immunodiagnostic assays for LEV. The synthesis methods described herein include chirally-selective, liquid-phase synthesis steps to produce selected LEV derivatives in high-yield. LEV derivatives can include operative groups, such as: immunogenic moieties that can be used to prepare anti-LEV antibodies; antigenic moieties that can be used in immunodiagnostic assays for LEV; or tracer moieties that can be used in immunodiagnostic assays. Additionally, the LEV derivatives can be used in immunodiagnostic assays to compete with LEV for anti-LEV antibodies.

  Levetiracetam (LEV)衍生物，合成LEB衍生物的方法，以及用于LEV的免疫诊断试验。本文所描述的合成方法包括手性选择性、液相合成步骤，以高产率生产选定的LEV衍生物。LEV衍生物可以包括操作基团，例如：可用于制备抗LEV抗体的免疫原性基团；可用于LEV的免疫诊断试验中的抗原性基团；或可用于免疫诊断试验中的示踪基团。此外，LEV衍生物可以用于免疫诊断试验，以与抗LEV抗体竞争LEV。
• PROCESS FOR THE PREPARATION OF 2-OXO-1-PYRROLIDINE DERIVATIVES
  申请人：Surtees John

  公开号：US20080009638A1

  公开（公告）日：2008-01-10

  The present invention relates to alternative processes for the preparation of 2-oxo-1-pyrrolidine derivatives of formula (I) Particularly, the present invention relates to alternative processes for the synthesis of levetiracetam, brivaracetam and seletracetam.

  本发明涉及制备式(I)的2-氧代-1-吡咯烷衍生物的替代工艺，特别地，本发明涉及左乙拉西坦、布利维拉西坦和赛乐替坦的合成的替代工艺。
• Cyclic sulfamide derivatives and methods of use
  申请人：——

  公开号：US20040023974A1

  公开（公告）日：2004-02-05

  Compounds of the formula 1 provide pharmacological agents which are inhibitors of PTPases, in particular, the compounds of formula I inhibit PTP-1B and TC PTP, and thus may be employed for the treatment of conditions associated with PTPase activity. The compounds of the present invention may also be employed for inhibition of other enzymes with a phosphotyrosine binding region such as the SH2 domain. Accordingly, the compounds of formula I may be employed for prevention or treatment of insulin resistance associated with obesity, glucose intolerance, diabetes mellitus, hypertension and ischemic diseases of the large and small blood vessels. The compounds of the present invention may also be employed in the treatment, prevention or control of a number of conditions that accompany Type 2 diabetes, including hyperlipidemia, hypertriglyceridemia, atherosclerosis, vascular restenosis, irritable bowel syndrome, pancreatitis, adipose cell tumors and carcinomas such as liposarcoma, dyslipidemia, and other disorders where insulin resistance is indicated. In addition, the compounds of the present invention may be employed to treat or prevent cancer, osteoporosis, neurodegenerative and infectious diseases, and diseases involving inflammation and the immune system.

  公式1的化合物可提供药理学制剂，这些制剂是PTP酶的抑制剂，特别是公式I的化合物抑制PTP-1B和TC PTP，因此可用于治疗与PTP酶活性相关的疾病。本发明的化合物也可用于抑制其他具有磷酸酪氨酸结合区域（如SH2结构域）的酶。因此，公式I的化合物可用于预防或治疗与肥胖、葡萄糖不耐受、糖尿病、高血压和大、小血管缺血性疾病相关的胰岛素抵抗。本发明的化合物还可用于治疗、预防或控制伴随2型糖尿病的许多疾病，包括高脂血症、高三酰甘油血症、动脉粥样硬化、血管再狭窄、肠易激综合征、胰腺炎、脂肪细胞肿瘤和脂肪肉瘤、脂质代谢异常以及其他表现为胰岛素抵抗的疾病。此外，本发明的化合物还可用于治疗或预防癌症、骨质疏松症、神经退行性和传染性疾病以及涉及炎症和免疫系统的疾病。
• Carbazole derivative, solvate thereof, or pharmaceutically acceptable salt thereof
  申请人：Zeria Pharmaceutical Co., Ltd.

  公开号：US08329913B2

  公开（公告）日：2012-12-11

  An object of the present invention is to provide novel carbazole derivatives, solvates thereof, or pharmaceutically acceptable salts thereof having an excellent adipose tissue weight reducing effect, hypoglycemic effect, and hypolipidemic effect, which are useful as a preventive and/or therapeutic agent for fatty liver, obesity, lipid metabolism abnormality, visceral adiposity, diabetes, hyperlipemia, impaired glucose tolerance, hypertension, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and the like. The above-mentioned object can be achieved by carbazole derivatives, solvates thereof, or pharmaceutically acceptable salts thereof, wherein the carbazole derivatives are represented by the following general formula (I): (In the formula (I), the ring A represents phenyl group or the like; X represents —O— or the like; Y represents ═N— or the like; a and b represent methylene group or the like; both V and Z represent —O— or the like; W represents a C1-C10 alkylene group whose 1 or 2 hydrogen atoms may be substituted by a phenyl group or a C1-C6 alkyl group; 1,2-phenylene group; 1,3-cyclohexyl group; or the like; R1 represents methyl group or the like; R2 represents methoxy group or the like; and R3 represents carboxy group or the like.).

  本发明的目的是提供具有出色的脂肪组织减重效果、降血糖作用和降脂作用的新型咔唑衍生物、其溶剂化物或药学上可接受的盐，其可用作脂肪肝、肥胖症、脂质代谢异常、腹部脂肪堆积、糖尿病、高脂血症、糖耐量受损、高血压、非酒精性脂肪肝病、非酒精性脂肪性肝炎的预防和/或治疗剂。通过咔唑衍生物、其溶剂化物或药学上可接受的盐可以实现上述目的，其中咔唑衍生物由下述通式(I)表示：（在式(I)中，环A表示苯基或类似基团；X表示-O-或类似基团；Y表示═N-或类似基团；a和b表示亚甲基基团或类似基团；V和Z均表示-O-或类似基团；W表示C1-C10烷基基团，其1或2个氢原子可以被苯基或C1-C6烷基基团取代；1,2-苯基基团；1,3-环己基基团或类似基团；R1表示甲基基团或类似基团；R2表示甲氧基基团或类似基团；R3表示羧基或类似基团。）